(Q50925969)

25 March 2018

title

PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model. (English)

1 reference

25 March 2018

author name string

J Du

1

1 reference

25 March 2018

M Yang

2

1 reference

25 March 2018

S Chen

3

1 reference

25 March 2018

D Li

4

1 reference

25 March 2018

Z Chang

5

1 reference

25 March 2018

Z Dong

6

1 reference

25 March 2018

language of work or name

English

0 references

publication date

12 October 2015

1 reference

25 March 2018

published in

Oncogene

1 reference

25 March 2018

volume

35

1 reference

25 March 2018

issue

25

1 reference

25 March 2018

page(s)

3314-3323

1 reference

25 March 2018

Regulation of cancer cell metabolism

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

How cancer metabolism is tuned for proliferation and vulnerable to disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Targeting PI3K/mTOR signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Phosphorylation and activation of p70s6k by PDK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells: CHARACTERIZATION OF A SELECTIVE ALLOSTERIC KINASE INHIBITOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

PDK1 coordinates survival pathways and beta-adrenergic response in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Complex networks orchestrate epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Perturbations of the AKT signaling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Mechanistic target of rapamycin complex 1 (mTORC1)-mediated phosphorylation is governed by competition between substrates for interaction with raptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

A novel and selective PDK1 inhibitor reduces breast cancer cell invasion and tumour growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

PTEN mutation, methylation and expression in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.393

p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells

31 March 2020

1 reference

12 December 2020

Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1

1 reference

12 December 2020

3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.

1 reference

12 December 2020

Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha.

1 reference

12 December 2020

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer

1 reference

12 December 2020

PDK1: the major transducer of PI 3-kinase actions

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2015.393

1 reference

25 March 2018

1 reference

25 March 2018